News
CSTL
21.56
-3.71%
-0.83
Castle Biosciences (CSTL) Investor Presentation - Slideshow
Seeking Alpha · 1d ago
Insider Sell: Castle Biosciences
Insider Sell: Castle Biosciences
MT Newswires · 03/16 16:46
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 03/08 21:31
SVB Securities Keeps Their Buy Rating on Castle Biosciences (CSTL)
TipRanks · 03/03 05:15
Analysts’ Top Healthcare Picks: Lumos Pharma (LUMO), Castle Biosciences (CSTL)
TipRanks · 03/02 16:30
Stephens & Co. Reiterates Overweight on Castle Biosciences, Maintains $41 Price Target
Benzinga · 03/02 15:44
BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
TipRanks · 03/02 11:25
Baird Maintains Outperform on Castle Biosciences, Lowers Price Target to $38
Benzinga · 03/01 14:19
--Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating
--Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating
MT Newswires · 03/01 12:10
BRIEF-Castle Biosciences Reports Fourth Quarter And Full-Year 2022 Results
Reuters · 02/28 22:24
Castle Biosciences GAAP EPS of -$0.78 beats by $0.06, revenue of $38.34M in-line, guidance above consensus
Seeking Alpha · 02/28 22:00
Earnings Scheduled For February 28, 2023
Benzinga · 02/28 09:34
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
NASDAQ · 02/27 14:40
Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M
Seeking Alpha · 01/09 07:28
Castle Biosciences Expects to Meet or Surpass Top End of 2022 Revenue Guidance Range
Castle Biosciences Expects to Meet or Surpass Top End of 2022 Revenue Guidance Range
MT Newswires · 01/09 05:35
Castle Biosciences Announced Preliminary FY 2022 Total Revenue Expected To Meet Or Exceed Top End Of Guided Range Of $132M–137M vs 135.47M Est
Benzinga · 01/09 00:18
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target
MT Newswires · 01/05 09:07
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Its products include DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, TissueCypher and IDgenetix. DecisionDx-Melanoma is a gene expression profile test developed to identify the risk of metastasis in patients with invasive cutaneous melanoma.